ArticleProceedings of the National Academy of Sciences of the United States of America2026
Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination.
Jun Nishida, Marco Seehawer, Ernesto Rojas Jimenez, Pengze Yan, Triet M Bui, Pierre Foidart, Hiromi Muramatsu, Marie-Anne Goyette, Xinran Cai, Zheqi Li and 3 more
Abstract read
In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Marco SeehawerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Ernesto Rojas JimenezDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Pengze YanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Triet M BuiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Pierre FoidartDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-1544-1493 Marie-Anne GoyetteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Xinran CaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Zheqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Mitchell B BeattieAcuitas Therapeutics, Vancouver, BC, Canada V6T 1Z3.
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0003-1008-6242 Funding
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2MInnovative mRNA vaccines to enhance the efficacy of T-cell transfer therapies against solid tumorsR01CA283736 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Norbert Pardi, Caius Gabriel Radu · 2024 to 2026
$3.1MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6MAmerican Brain Tumor Association (ABTA) NABelgian American Educational Foundation (BAEF) NACancer Prevention Initiative (CPI) NADaiichi Sankyo Foundation of Life Science NAHHS | NIH | National Cancer Institute (NCI) CA236754 CA283736HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI153064MEXT | Japan Society for the Promotion of Science (JSPS) NANCI NIH HHS R01 CA283736NCI NIH HHS T32 CA236754NIAID NIH HHS R01 AI153064Susan G. Komen (SGK) NAUehara Memorial Foundation (UMF) NAWallonie-Bruxelles International (WBI) NA
6 · The paper itselfAbstract
Tumor-suppressive immunity is more evident in early-stage compared to advanced tumors making it the ideal point for cancer interceptive immunotherapies. We previously described that higher peripheral T cell diversity is associated with more pronounced CD8
Indexed as
Breast NeoplasmsCancer VaccinesLactalbuminMammary Neoplasms, ExperimentalNanoparticlesRNA, MessengerAnimalsFemaleLipidsLiposomesmRNA VaccinesRatsRats, Sprague-DawleyVaccinationCancer VaccinesLactalbuminLipid NanoparticlesLipidsLiposomesmRNA VaccinesRNA, Messengerbreast cancercancer preventionmRNA-LNP vaccineprogenitors
Identifiers
PMID42685084
PMCPMC13552656
What Socratic holds
Textmetadata
Read underepoch 390